mAbxience Argentina
Buenos Aires – Munro
History
Founded in 2008 by a team of scientists with over 35 years’ experience in the development and production of biopharmaceuticals, with expert knowledge of GMPs * and regulatory pathways.
The plant at Munro is mAbxience’s first industrial plant and also the first in South America to produce monoclonal antibodies with single use technology.
It benefits from a young, multidisciplinary and international professional and passionate team actively contributing to training local young people in the field of biotechnology.
Facilities
Our production platform is single-use based, following the strictest international guidelines for biotechnological companies.
From 2012, our plant is dedicated to the commercial production of Biosimilars monoclonal antibodies, with two products in the market. In 2014, the first biosimilar monoclonal antibody was registered in Argentina (MB01 rituximab) and in 2016, the second (MB02 bevacizumab).
The Munro plant is a R&D center of excellence, specialized in the development and process optimization for biopharmaceuticals.
Regulatory agencies approvals
mAbxience Buenos Aires plant has several GMP certificates from several international agencies, such as COFEPRIS (Mexico), ANMAT (Argentina), counting also with Turkey and Colombia, among others.
*GMP: (Good Manufacturing Practices)
